Pablo Legorreta and the price of waiting

The curious thing about Pablo Legorreta’s business is that somebody else usually did the inventing. Somebody else signed the original agreement, developed the product, or arranged to receive a small percentage of its sales. Then came the waiting. Legorreta found a career in that interval, between owning something valuable and having the money available to spend.

In the early 1990s, he was working at Lazard Frères, the investment bank, and buying royalty interests through small investment vehicles. He had encountered an earlier financing model associated with PaineWebber: private investors put up capital and received rights to future payments. Legorreta began buying those rights from the original investors. An agreement that looked like a long succession of receipts could also have a price today.

“We were doing it small scale with a few friends,” he recalled in 2013. It is a pleasingly modest description of the beginning. No grand headquarters is required to see a mismatch between two people’s calendars. One owner wants cash now. Another investor can afford to wait. The difficult part is agreeing what the waiting is worth.

In 1996, Legorreta left Lazard and established Royalty Pharma with Rory Riggs. They raised $60 million. By June 2020, the company was pricing a public offering of approximately $2.18 billion. Those numbers describe different things, an initial pool of investment capital and a later share offering. Between them sits almost a quarter-century of persuading people that royalty rights could support an enduring business.

01An engineer takes the financial route

Legorreta studied industrial engineering at Universidad Iberoamericana in Mexico City. He attended the university from 1981 to 1985. His professional route then took him to Lazard in Paris and New York, working in investment banking before he founded his own firm. The transactions began before the company did.

In 1993 and 1994, he developed acquisition vehicles for two royalty investments. These early arrangements matter because they give the founding date some texture. By the time he left the bank in 1996, he had already been working with the mechanism. Royalty Pharma emerged from repeated transactions, with a structure that could be expanded, rather than from a product awaiting its first customer.

There is a quieter part of his upbringing, too. He grew up in a small town south of Mexico City and has described his mother as socially conscious. As a teenager, he joined family volunteer work, painting walls, cleaning up, and collecting donations. These are unusually practical details in a financier’s biography. Before the capital allocations came jobs that required a bucket, a brush, and an afternoon.

The childhood recollection does not explain every later decision. It does suggest why the people and institutions on the receiving side of a transaction belong in his story. A royalty owner has ambitions and a budget as well as an asset. Legorreta’s business requires understanding all three. A spreadsheet may set the terms; it cannot decide what the seller hopes to do next.

02What a slice of sales can buy

To understand the proposition, imagine an institution entitled to a share of a product’s future sales. It could keep collecting the payments as they arrive. Or it could sell some or all of that entitlement for an upfront sum. Royalty Pharma supplies the money and acquires the agreed economic interest. The institution gains spending power immediately, while the buyer takes responsibility for judging the future receipts.

The distinction between a royalty and a whole company is central. An interest in sales does not, by itself, confer ownership of the seller’s entire operation. This lets a negotiation focus on a particular asset and its cash flows. For a seller, that can offer another route alongside issuing shares, borrowing, or selling a business. Each choice gives up something different. Receiving tomorrow’s money today has a price.

Legorreta also co-founded Pharmakon Advisors, which provides debt capital to the life sciences industry. It is a useful companion fact: his career has involved more than one financing instrument. Royalties and loans address different arrangements between capital providers and businesses. His recurring subject is how to put capital to work against assets whose commercial lives unfold over years.

The attraction of a royalty purchase is easy to explain at a dinner table. Evaluating one is less sociable. How durable are sales? How long does the agreement last? What could a competitor change? A percentage sign is admirably concise, but it leaves an investor with a great deal of reading. The elegance of the arrangement depends on work that has very little elegance about it.

03Giving the company a longer clock

The business itself needed a suitable timetable. Royalty Pharma began with funds that had finite lives. In 2004, it converted to an evergreen structure, giving the enterprise an indefinite life. A fund with an approaching end date and an asset with years of payments remaining can have an awkward conversation. An ongoing company has more room to decide when to invest again.

Borrowing became another part of the design. Royalty Pharma raised $190 million in debt in 2003. Over time, its financing arrangements evolved as the portfolio expanded. The commercial logic is straightforward: a collection of income-producing interests can support a different funding structure from one isolated bet. The quality and variety of those interests still matter. Putting several uncertainties together does not make them disappear.

These changes are part of Legorreta’s achievement as an operator. Buying an attractive asset is one task. Creating an organization able to keep buying, paying its obligations, and considering the next opportunity is another. His career contains a series of adjustments to the machinery around the investments. The financing structure became a continuing project in its own right.

That gives the growth story a less theatrical shape than the usual founder legend. There is no need to locate one heroic afternoon. The significant decisions stretch across years: start buying rights, build a company, add borrowing, extend its life, open its ownership to public investors. Patience belongs on both sides of the desk. The purchaser of future payments must also build an organization capable of receiving them.

04A ticker symbol after 24 years

In June 2020, Royalty Pharma priced 77,681,670 shares at $28 each. Of those, 60 million were newly offered by the company; the remainder came from selling shareholders. The distinction matters. The offering provided capital for the business and an opportunity for some existing investors to sell. A public debut can serve more than one constituency without making their interests identical.

Trading began on Nasdaq on June 16 under RPRX. For Legorreta, the listing arrived 24 years after the founding. That interval is worth sitting with. Public markets encountered a business that had already spent decades assembling transactions and revising its financial structure. The ticker was a new way to own it, attached to an operation with a substantial private history.

Public ownership also brought a different audience. A private agreement can be explained around a table. A listed company must communicate through results, disclosures, and recurring conversations with shareholders. Legorreta’s appearances at investor conferences now offer a regular view of how he describes the business. He speaks about funding capacity, repeat relationships, and the willingness of potential partners to consider royalties.

At a January 2025 conference, he described an evolution in those conversations: “Today, companies come to us.” The earlier task had involved explaining the model at other people’s doors. The later one involved responding to demand. It is a small sentence with a considerable entrepreneurial distance inside it. An idea has become easier to discuss when the other side already knows its name.

“Today, companies come to us.”

PABLO LEGORRETA · JANUARY 2025

05The founder changes his own arrangement

The next consequential transaction was closer to home. Until 2025, Royalty Pharma relied on an external management company, RP Management, for its operations and personnel. Legorreta had been that manager’s sole owner before 2024. So there were two economic arrangements to consider: the public company’s royalty portfolio and the separate organization being paid to run it.

Royalty Pharma completed the acquisition of the manager on May 16, 2025. Employees of the manager became employees of Royalty Pharma. The company stopped operating under the external arrangement, which had charged fees linked to portfolio receipts and securities investments. Shareholders approved the proposal with 99.9% of votes cast in favor. An administrative-sounding change reached directly into the relationship between management and owners.

Legorreta’s own position changed with it. He agreed that the equity he received would vest over five years, although his previous ownership had carried no vesting requirement. This is a particularly revealing detail in a career built around the timing of payments. The founder accepted a new timetable for his own stake. The transaction made alignment a contractual matter as well as a statement of intent.

06Still thinking in years

By August 5, 2026, Royalty Pharma was reporting $773 million in second-quarter Portfolio Receipts, up 6% from a year earlier. Royalty Receipts, the recurring component, were $768 million, up 14%. The difference between those measures matters: the broader figure also includes milestones and other contractual receipts. Even the headline numbers require attention to what, exactly, is arriving and when.

The company raised its full-year Portfolio Receipts guidance to $3.4 billion-$3.5 billion. That was a forecast, rather than a completed result. Legorreta’s stated ambition remained consistent with his history: allocate capital in life sciences and build compounding growth. After 30 years, his company was still evaluating opportunities that required estimates about a future it could not dictate.

Away from the earnings calendar, his institutional roles include the New York Academy of Sciences and Park Avenue Armory. The latter adds an arts organization to a professional life dominated by financial agreements. In April 2021, he also sat for an Entrepreneurs Edge interview intended for Stony Brook business students. A founder who once had to explain a financing idea now has a long company history to explain with it.

The useful question in Legorreta’s story is what happens after a valuable idea already exists. Who owns the right to its income? Who needs money sooner? Who can wait, and on what terms? He made those questions the foundation of Royalty Pharma. The answers have required new structures, fresh capital, and occasional changes to his own arrangements. Thirty years is a long time to keep revising an answer. It is also rather the point.